Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Improving Modern Vaccines

By Drug Discovery Trends Editor | March 8, 2016

Caption to Figure: Schematic diagram of a Glycovaccine construct of sugar-polymer tails (shown as red zig-zag lines) connected to a globular protein core (shown in blue). The flexible sugar (carbohydrate) polymers control the physical properties in vaccine formulations and provide a protective cloud (red shade) against protein denaturation and vaccine effectiveness. Source: The University of Nottingham Millions of people – particularly infants in underdeveloped countries — suffer from the serious life threatening illnesses of meningitis, pneumonia and influenza. These are due to infection by microbes such as N. meninigitidis, S. pneumoniae and H. influenzae b.

Early vaccines were based on the large and complex carbohydrate (sugar) based polymers produced by the bacteria. More recently new glycoconjugate vaccines have been developed which involves ‘fusing’ the complex carbohydrates — the sugar polymer tails — onto carrier proteins. These sugar-protein complexes improve the effectiveness and longevity of the vaccine. However, there are still problems concerning the stability of formulations they are prepared in.

Scientists at The University of Nottingham’s National Centre for Macromolecular Hydrodynamics have just published the third in a series of papers showing that the sugar chains control the physical behavior of these vaccines in the aqueous preparations used in their delivery. It is hoped this research into the hydrodynamic properties of vaccine preparations will help lead to the development of improved and more stable vaccines.

The latest study published, in the Nature journal Scientific Reports — led by Steve Harding, Professor of Applied Biochemistry in the School of Biosciences and Dr Gary Adams an expert in Diabetes Health and Therapeutics in the School of Health Sciences, was carried out in collaboration with colleagues at GSK vaccines in Belgium.

Using the latest ‘hydrodynamic’ techniques and approaches — many of which have been developed in their laboratory — Professor Harding and Dr Adams found that the protein has a compact globular conformation whereas the carbohydrate polymers have much more extended flexible structures.

The conjugates were not only found to be over 50 times larger than the protein (and about 10 times larger than the individual carbohydrate polymers) but also retained the highly flexible properties of the carbohydrate: the attached carbohydrate chains flop all over the place effectively encapsulating the protein and protecting it from denaturation, which can cause breakage and loss of effectiveness. Conjugation strategies need to ensure the carbohydrate chains are long enough to achieve this coverage.

Professor Harding said: “We believe this is an exciting development. Carbohydrates are often underestimated in terms of their therapeutic importance — they still have a sort of ‘Cinderella’ status in biochemistry.

“The stability of vaccine preparation is of particular concern under hot climate conditions and until now, nobody has been quite sure about the relative roles the sugar and protein components play in the properties of these substances. Understanding that would be a big step in producing more stable and effective vaccines.”

Source: University of Nottingham


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE